Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Kiev declares energy emergency after Russian attacks amid winter cold - 2Understanding Preschool Projects: An Extensive Aide
- 35 Home Improvement Styles: Decision in favor of Your #1
- 4The Response Uncovered: Disentangling the Secrets of the Universe
- 5Israel faces tough choices over haredi draft exemptions, legal expert warns
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- From Squid Game to Your Party! Six Entertaining Test Games That Will Have You in Join
- How we came to be: Scientists get first look at the evolution of early complex animals
- Must-See Attractions in Australia
- Volkswagen Just Revealed a Massive Range-Extended SUV for China, and America Isn’t Getting It
- 6 Fun Urban areas For Seniors To Travel
- Divorce filings, feuds and legal trouble: The 'Mormon Wives' drama keeps piling up
- NASA funds new tech for upcoming 'Super Hubble' to search for alien life: 'We intend to move with urgency'
- 80 km. on foot: Sharren Haskel’s three-day march in protest of haredi draft bill
